Macular Degeneration – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Macular Degeneration Market Outlook

Thelansis’s “Macular Degeneration Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Macular Degeneration treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Macular Degeneration Overview

Macular degeneration, an age-related retinal disease, is characterized by a gradual central visual acuity decline, primarily due to neovascularization in the subretinal space, partly driven by vascular endothelial growth factor (VEGF) activity. In its early stages, macular degeneration can manifest subtly:

1. Gradual loss of clear object perception.
2. Objects may seem distorted in shape.
3. Straight lines can appear wavy or irregular.
4. A diminished ability to perceive colors distinctly.
5. Development of a dark or empty spot at the center of one's vision.

The underlying causes of macular degeneration remain unidentified. Notably, women tend to experience AMD earlier than men. This condition occurs in two forms: "dry" (atrophic) and "wet" (exudative), with the majority of cases falling into the dry category. Unfortunately, no specific treatment exists for dry AMD. However, recent advancements have introduced various agents targeting VEGF, which have shown promise in slowing the progression of neovascular or "wet" macular degeneration when administered via intravitreal injections. These agents include monoclonal antibodies to VEGF (such as bevacizumab and ranibizumab), aptamers (small oligonucleotides binding to VEGF, like pegaptanib), and fusion VEGF receptor proteins acting as decoys for the circulating growth factor (e.g., aflibercept). The primary risk factor for macular degeneration is age, with a higher prevalence among those with a family history, Caucasians, and smokers. Women are more susceptible to age-related macular degeneration, and additional risk factors include high blood pressure, high cholesterol, heart disease, light-colored irises, sun exposure, farsightedness, and a diet lacking in fish.

• Approximately 19.8 million Americans aged 40 and above, accounting for 12.6% of the population, were estimated to be living with age-related macular degeneration (AMD).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: